StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)

Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –

Actinium Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Actinium Pharmaceuticals's price to sales ratio was 384.8× on Apr 30, 2026, against 74.7× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 2026384.8×+165.4
2023Apr 28, 2023219.4×−35.6
2022Dec 30, 2022255.0×–

More Actinium Pharmaceuticals figures

See a number that looks wrong?